← Leaderboards
Courtney S Young
Myogene Bio, Llc
$3,772,804
Attributed
$3,772,804
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.3M · FY2019–25$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,772,804 · 6
By mechanism
R44$2,509,835 · 2
R21$613,750 · 2
SB1$499,300 · 1
R43$149,919 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Genes”
- Leonard Freedman · Leidos Biomedical Research, Inc.$97,908,773
- Yunda Huang · Fred Hutchinson Cancer Center$51,342,169
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Lynn Briscoe · Leidos Biomedical Research, Inc.$41,311,588
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Evan Z Macosko · Broad Institute, Inc.$32,734,698
Research focus
GenesExonsMouse ModelDystrophinReading FramesMutationHumanized MouseCrispr/Cas TechnologyDuchenne Muscular DystrophyWasting SyndromeMuscleBecker Muscular DystrophyMuscular AtrophyDoseAdvanced DevelopmentProteinsVectorCessation Of LifePrematureCohortDependovirusInjectionsIn VivoAlleles
Grant awards (9)
Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy$1,321,604
R44 · FY2025 · NS · contact PI
Advancing manufacturing and release testing of a gene editing therapy for Duchenne muscular dystrophy$499,300
SB1 · FY2025 · AR · contact PI
Assessment of restoration of an internally deleted dystrophin as a surrogate biomarker for future clinical trials of a gene editing therapy in Duchenne muscular dystrophy$302,500
R21 · FY2025 · HD · contact PI
Durability of a gene editing therapy that restores dystrophin in a humanized mouse model of Duchenne muscular dystrophy$201,250
R21 · FY2025 · TR · contact PI
Durability of a gene editing therapy that restores dystrophin in a humanized mouse model of Duchenne muscular dystrophy$110,000
R21 · FY2024 · TR · contact PI
Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy$499,207
R44 · FY2022 · AR · contact PI
Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy$493,728
R44 · FY2020 · AR · contact PI
Comparison of single versus dual vector delivery of AAV-SPY-DYS45-55 for Duchenne muscular dystrophy$149,919
R43 · FY2020 · AR · contact PI
Pre-clinical development of SPY-DYS45-55, a CRISPR/Cas9 platform for Duchenne muscular dystrophy$195,296
R44 · FY2019 · AR · contact PI